Blutungen unter direkten oralen Antikoagulanzien

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Medizinische Klinik - Intensivmedizin und Notfallmedizin

• Publication date

  2018-05-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1007/s00063-018-0436-8PMID 29728712
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Association of Intracerebral Hemorrhage Among Patients Taking Non–Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality

  2018cited by this paper
• Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa.

  2017cited by this paper
• Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study.

  2017cited by this paper
• 2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.

  2017cited by this paper
• Idarucizumab for Dabigatran Reversal — Full Cohort Analysis

  2017cited by this paper
• Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy.

  2017cited by this paper
• Idarucizumab for Dabigatran Reversal Full Cohort Analysis

  2017cited by this paper
• Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review

  2017cited by this paper
• Point-of-Care Warfarin Monitoring in the ROCKET AF Trial.

  2016cited by this paper
• Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.

  2016cited by this paper
• A rapid pro-hemostatic approach to overcome direct oral anticoagulants

  2016cited by this paper
• Edoxaban Effects on Bleeding Following Punch Biopsy and Reversal by a 4-Factor Prothrombin Complex Concentrate

  2015cited by this paper
• Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis

  2015cited by this paper
• Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta‐analysis of randomized controlled trials

  2015cited by this paper
• Neither dabigatran nor rivaroxaban were linked to increased GI bleeding compared with warfarin

  2015cited by this paper
• Hemodialysis for the treatment of dabigatran‐associated bleeding: a case report and systematic review

  2015cited by this paper
• Intermittent haemodialysis and continuous veno‐venous dialysis are effective in mitigating major bleeding due to dabigatran

  2015cited by this paper
• Idarucizumab for Dabigatran Reversal.

  2015cited by this paper
• Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH: reply

  2015cited by this paper
• Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH

  2015cited by this paper
• Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis

  2015cited by this paper
• Use of PER977 to reverse the anticoagulant effect of edoxaban.

  2014cited by this paper
• The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis.

  2014cited by this paper
• Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial.

  2014cited by this paper
• New Oral Anticoagulants in Elderly Adults: Evidence from a Meta‐Analysis of Randomized Trials

  2014cited by this paper
• How I treat target-specific oral anticoagulant-associated bleeding.

  2014cited by this paper
• The successful management of dabigatran-associated critical end-organ bleeding with recombinant factor VIIa

  2014cited by this paper
• Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta‐analysis

  2014cited by this paper
• Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.

  2014cited by this paper
• Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.

  2014cited by this paper
• Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests

  2014cited by this paper
• Activated prothrombin complex concentrate for the prevention of dabigatran‐ associated bleeding

  2014cited by this paper
• A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa

  2013cited by this paper
• Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro

  2013cited by this paper
• Dabigatran and postmarketing reports of bleeding.

  2013cited by this paper
• Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban

  2013cited by this paper
• A specific antidote for dabigatran: functional and structural characterization.

  2013cited by this paper
• Dabigatran-associated subdural hemorrhage: using thromboelastography (TEG®) to guide decision-making

  2013cited by this paper
• Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates

  2013cited by this paper
• New Oral Anticoagulants: Comparative Pharmacology with Vitamin K Antagonists

  2013cited by this paper
• Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma.

  2012cited by this paper
• Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model

  2012cited by this paper
• Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors

  2012cited by this paper
• Effect of rivaroxaban on blood coagulation using the viscoelastic coagulation test ROTEM™

  2012cited by this paper
• Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban

  2012cited by this paper
• Edoxaban

  2011cited by this paper
• Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate

  2010cited by this paper
• The Risk for and Severity of Bleeding Complications in Elderly Patients Treated with Warfarin

  1996cited by this paper

• No citing papers are available for this paper.